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Abstract
Background: Early and accurate prediction of response to cancer treatment through imaging criteria is particularly
important in rapidly progressive malignancies such as Glioblastoma Multiforme (GBM). We sought to assess the
predictive value of structural imaging response criteria one month after concurrent chemotherapy and
radiotherapy (RT) in patients with GBM.
Methods: Thirty patients were enrolled from 2005 to 2007 (median follow-up 22 months). Tumor volumes were
delineated at the boundary of abnormal contrast enhancement on T1-weighted images prior to and 1 month after
RT. Clinical Progression [CP] occurred when clinical and/or radiological events led to a change in chemotherapy
management. Early Radiologic Progression [ERP] was defined as the qualitative interpretation of radiological
progression one month post-RT. Patients with ERP were determined pseudoprogressors if clinically stable for ≥6
months. Receiver-operator characteristics were calculated for RECIST and MacDonald criteria, along with alternative
thresholds against 1 year CP-free survival and 2 year overall survival (OS).
Results: 13 patients (52%) were found to have ERP, of whom 5 (38.5%) were pseudoprogressors. Patients with ERP
had a lower median OS (11.2 mo) than those without (not reached) (p < 0.001). True progressors fared worse than
pseudoprogressors (median survival 7.2 mo vs. 19.0 mo, p < 0.001). Volume thresholds performed slightly better
compared to area and diameter thresholds in ROC analysis. Responses of > 25% in volume or > 15% in area were
most predictive of OS.
Conclusions: We show that while a subjective interpretation of early radiological progression from baseline is
generally associated with poor outcome, true progressors cannot be distinguished from pseudoprogressors. In
contrast, the magnitude of early imaging volumetric response may be a predictive and quantitative metric of
favorable outcome.
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Background
In 1990, MacDonald et al [1] reported criteria for
response assessment in glioma. Importantly, these criteria
incorporated features such as time factors, degree of
response of contrast-enhancing tumor using computed-
tomography (CT)-based uni-dimensional World Health
Organization (WHO) criteria [2], neurologic status and
the use of corticosteroids. Although these criteria have
become widely accepted, they have also been criticized
for their limitations [3-5], including their inability to
accurately assess complex tumor morphology, account
for non-tumor factors that may cause contrast enhance-
ment, reaction to local therapies [6], and lack of applic-
ability to non-enhancing tumors. Furthermore, the
phenomenon of ‘pseudoprogression’ observed in patients
receiving concurrent chemo-radiotherapy [7-9], as well
as the dilemma of ‘pseudo-response’ seen with some of
the newer anti-angiogenic therapies [5,10], adds to the
already complex challenge of early assessment as these
phenomena can confound image interpretations.
The accurate and early prediction of response and/or
progression remains important for several reasons. In
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comparison of novel therapies [5]. Secondly, such a bio-
marker could be utilized as a surrogate endpoint in clin-
ical trials, thus conferring the distinct advantage of
earlier response prediction and greater opportunity to
amend or institute alternate therapies, especially given
the aggressive nature of Glioblastoma Multiforme
(GBM). Thirdly, earlier imaging predictors could poten-
tially allow the conduct of smaller clinical trials requir-
ing fewer patients, enable earlier judgements about
promising versus futile therapies, more expeditious reg-
ulatory approval for new drugs, and ultimately earlier
application and translation of new therapies into clinical
practice [11,12]. In reality however, the evidence for reli-
able imaging response thresholds that could ultimately
influence therapeutic decision making is still lacking.
Currently, response criteria are largely based on the
response evaluation criteria in solid tumors (RECIST)
guidelines [13,14], which were developed to standardize
reporting of outcomes of clinical trials. Most recently,
the Response Assessment in Neuro-Oncology (RANO)
working group provided updated criteria for high-grade
gliomas [15], but as of yet there is not analysis of these
criteria as they relate to clinical endpoints such as over-
all survival and progression-free survival.
We embarked on a study investigating early structural
and functional magnetic resonance imaging (MRI) eva-
luations of response in patients with GBM. As a first
step, we sought to investigate the predictive value of
standard structural imaging response criteria one month
after the delivery of concurrent chemotherapy and
radiotherapy (RT). We also undertook exploratory ana-
lysis of alternate structural imaging response thresholds
that may better correlate with and/or predict for clinical
outcomes.
Methods
This study was approved by the institutional research
ethics board. Patients were prospectively enrolled over a
26 month interval between May 2005 and July 2007.
Patients were approached for enrollment if they met the
following criteria: histological diagnosis of WHO grade
IV Glioblastoma Multiforme; planned to receive defini-
tive concurrent chemotherapy (temozolomide 75 mg/m
2
daily) and RT (60Gy in 30 fractions over 6 weeks) fol-
lowed by adjuvant temozolomide chemotherapy (200
mg/m
2 × 5 days, monthly for 1 year or until progres-
sion); age ≥18 years; and ECOG performance status 0 or
1. Patients were excluded if they had contraindications
to MRI, severe claustrophobia, or previous cranial radio-
therapy. Relevant clinical and demographic information,
including gender, age, diagnosis date, disease multi-
focality, surgical status, and radiation treatment dates
were also captured.
MRI acquisition was performed at the following time-
points: Baseline (BL) post-operatively but prior to radio-
t h e r a p y( R T ) ;w e e k3a n dw e e k6o fR T ,1m o n t ha f t e r
completion of RT, then every two months until evidence
of clinical progression (defined below) or until 1 year of
follow-up. All images were acquired using a 1.5 T GE
Signa Excite scanner (GE Healthcare, Waukesha, WI,
USA). The MRI acquisition protocol was performed as
follows: Axial post-contrast axial T1-weighted fast-spin
e c h o( F S E )( T E=2 0m s ,T R=4 1 6 . 6 6m s ,F A=9 0 ° ,
BW = 122.109, slice thickness = 5 mm, slice spacing = 7
mm, 0.859 × 0.859 × 7 mm resolution).
Clinical and imaging end-points included: A) Time to
Clinical Progression [CP] - interval between beginning
of RT and CP defined as aggregate of clinical and radi-
ological progression resulting in a change in patient
management (for example, second-line chemotherapy,
salvage surgery or palliative care); B) Overall Survival
[OS] - defined as the interval between beginning of RT
and death; C) Early Radiological Progression [ERP] -
qualitative impression of any radiological progression
from baseline to one month post-RT as defined by a
radiation oncologist (CM), and D) Pseudoprogression -
when ERP was present but the patient showed clinically
stable disease for at least 6 months post-RT without a
change in the adjuvant chemotherapy regimen.
Post-contrast axial T1-weighted FSE images were
rigidly co-registered (mutual information algorithm)
with the RT planning CT datasets using a commercial
radiotherapy treatment planning system (Pinnacle
3 v7.6c
and 8.1, Philips Radiation Oncology Systems, Madison,
WI). A radiation oncologist (ESK, NL) delineated tumor
volumes on the T1-weighted post-contrast MR images
as defined by areas of abnormal contrast enhancement
reflecting residual or recurrent tumor, whilst excluding
areas of post-surgical change. All volumes were then
reviewed and finalized by a diagnostic radiologist (EY).
Both longest diameter (axial, coronal, and sagittal
planes) and 3D volumetric data (cc) were computed at
baseline (BL) and one-month post RT. Progression was
then assessed via RECIST criteria, a 20% increase in the
longest tumor diameter or a 40% increase in volume
(sums of diameters or volumes were used in the case of
multi-focal disease). Disease response as determined by
RECIST was defined as a 65% decrease in volume or a
30% decrease in diameter. The MacDonald criteria were
also evaluated: progressive disease defined as a 25%
increase in the largest tumor area (cm
2)a n dr e s p o n s i v e
disease defined as a 30% decrease in largest area. Each
patient was then classified in a binary fashion, as either
having progressive or responsive disease based on these
imaging thresholds. In addition, the following range of
volume, area and diameter progression/response thresh-
olds (see Additional File 1 - Table 1) were investigated
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decrease up to > 5%, 15% or 30%; Area - any increase,
any increase or decrease > 5%; 15% or 30%; and Volume
- any increase, > 25% increase, any increase or decrease
> 10%; 25%; or 50%.
Sensitivity and specificity values were calculated for
each threshold using clinical progression-free survival at
1 year and overall survival at 2 years. Receiver-operator
curves (ROC) were also constructed and statistical ana-
lysis was performed on the basis of work by DeLong et.
al. [16]. Kaplan-Meier survival curves were created to
analyze early progression, pseudoprogression and clinical
progression as previously defined.
Results
A total of 30 patients were prospectively recruited. One
patient refused study procedures after enrollment and
another 4 patients did not undergo MRI examination
one month after RT, leaving a total of 25 patients from
whom imaging data was analyzed. It should be noted
that demographical and follow-up data was taken from
all 29 patients followed, however only the demographics
of the 25 patients analyzed in this study are reported
here. The median age of patients enrolled was 56 years
(15 men, 10 women, range 46 - 68 years). Five patients
presented with multifocal disease. Tumor volumes at
baseline ranged from 0.96 cm
3 to 143.2 cm
3. The major-
ity of patients were enrolled after gross total resection (n
= 14), while 8 and 3 patients underwent partial resection
and biopsy only, respectively.
The study cohort had a median follow-up of 26.3
months (range 13.3 - 37.7 months). Median survival was
high at 26.7 months and median time to clinical pro-
gression was 7.5 months (range 1.5 mo. - 35.9 mo.).
A qualitative impression of any radiological progres-
s i o n( E R P )f r o mb a s e l i n ew a sf o u n di n1 1p a t i e n t s
(40.0%), although only 2 patients strictly met the Mac-
Donald criteria for progression at 1 month. Median sur-
vival for patients with ERP was significantly shorter than
those without (11.2 mo vs. not reached, p < 0.001) (Fig-
ure 1). Of those with ERP, five were subsequently deter-
mined to have pseudoprogression (45.5% of ERP).
Pseudoprogressors fared better than true early progres-
sors, with a median survival of 19.0 months vs. 7.2
months (p < 0.001), (Figure 2)
Sensitivity and specificity values were calculated for each
response threshold, along with the positive and negative
likelihood ratios (+LH; -LH) and the area-under-the-curve
(AUC) for volume, area and diameter metrics (see Addi-
tional files 1, 2, 3 - Table 1, 2 and 3 respectively) in pre-
dicting for 2-year overall survival. The most sensitive tests
were those measuring response, namely greater than 25%
and 50% decreases in volume and 15% and 30% decreases
in area and diameter. The most specific tests were those
with the highest thresholds for progression, namely the
RECIST criteria for both volume and diameter, and Mac-
Donald criteria for area. In general, the volume measure-
ments consistently performed better in every category
than did the area and diameter metrics. This trend can
also be visualized in Figure 3, receiver-operator curves
plotting sensitivity vs. 1-specificity for the volume, area
and diameter thresholds against overall survival at 2 years.
T h er e s p e c t i v eA U C ’s are 0.83 (0.59 - 0.94 95% CI), 0.76
(0.53 - 0.90 95% CI) and 0.69 (0.44 - 0.84 95% CI) for
volume, area and diameter respectively. These values were
significantly different from chance (AUC of 0.5) for both
volume and area (p < 0.005 and p < 0.05, respectively) but
not for diameter (p > 0.1). When comparing amongst
AUC’s there was no significant difference between volume,
area or diameter, with the greatest trend seen between
volume and diameter (p > 0.1). The two most prognostic
thresholds were > 15% decrease in area (3.33 +LH, 0.22
-LH) and > 25% decrease in volume (3.38 +LH, 0.21 -LH).
Figure 1 Overall survival according to 1 month radiological
progression status: Overall. survival based on any early radiological
progression (ERP), observed one month after RT.
Figure 2 Overall survival according to true vs. pseudo-
progression status: Overall survival. based on true vs. pseudo
progression at one month.
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volume thresholds when predicting for progression-free
survival at 1 year and overall survival at 2 years, demon-
strating a trend that volume metrics to be more predictive
of overall survival at 2 years than PFS at 1 year (AUC 0.83
vs. 0.70, p < 0.2). Figure 5 depicts Kaplan-Meier survival
based on > 25% volume response at 1-month post RT
nearing statistical significance (median survival 14.9 mo
vs. not reached, p < 0.06).
Discussion
The early and accurate prediction of response to cancer
treatment through the application of imaging criteria
has several potential advantages. Ideally, imaging
thresholds would provide utility as surrogates for out-
come over and above the more traditional measures
including overall and progression free survival [17],
allowing for more expeditious conduct of clinical trials
(both phase II [18] and III). This in turn could lead to
the earlier institution of alternate therapies that show a
beneficial effect on outcome. This is particularly impor-
tant in dealing with aggressive and rapidly growing
malignancies such as GBM.
Our results show that across all thresholds, both pro-
gressive and responsive, volume was uniformly more
predictive of OS and PFS as seen by the right shift of
the diameter ROC curve in Figure 3 (AUC of 0.83 vs.
0.76 vs. 0.69). However this was only a trend, not
achieving significance amongst the three, the closest
being volume vs. diameter (p > 0.15). This is similar to
what Shah et al and Galanis et al have reported as cor-
relations between uni and multi-dimensional radiologi-
cal data in classifying progressive disease [19,20].
Furthermore, we show that a qualitative interpretation
of any radiological progression one-month post therapy
is associated with poor outcomes. However, this assess-
ment is not acted upon clinically because of the con-
founding potential for treatment effect (or
pseudoprogression), and our current inability (clinically
and radiologically) to distinguish the two groups apriori.
Many recent investigations have looked at the incidence
and outcomes related to pseudoprogression [21-24].
Two Canadian studies by Roldan et al and Sanghera et
al found rates of pseudoprogression of 40% and 32%
respectively, and median survivals of 9.1 months and
31.2 months [22,23]. Another recent study by Gerstner
et al found the pseudoprogression rate to be 57% with a
median survival of 24.4 months, however their definition
of pseuodprogression was at 3 months post-chemoRT
[24], compared to 6 months in this study (and the two
Figure 3 Receiver-Operator Curve by Dimension Metric:
Receiver-operator curves for volume (solid, square), area (dashed,
cross) and diameter (dashed, diamond) thresholds in predicting 2
year overall survival. Line of indecision is marked as a dotted line.
Figure 4 Receiver-Operator Curve of Volume Metrics by
Clinical End-point: Receiver-operator curves for volume thresholds
in predicting for 2 year overall survival (solid, square) and 1 year
clinical progression-free survival (dashed, diamond). Line of
indecision is marked as a dotted line.
Figure 5 Kaplan-Meier survival according to 25% Volume
Response at 1 month: Kaplan-Meier survival curve for patients
with and without a > 25% response in tumour volume, one month
after RT.
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difference in OS between those with pseudoprogression
a n dt h o s ew i t h o u tE R P .T h er e s u l t sf r o mt h i ss t u d y
were in keeping with other literature, including a rate of
pseudoprogression of 38.5% and a median survival of
19.0 months. There was also no survival benefit between
pseudoprogressors and those patients with no ERP,
however pseudoprgressors showed improved OS com-
pared with true early progressors (median survival 19.0
mo vs. 7.2 mo, p < 0.01), in keeping with the results of
Roldan and Sanghera [22,23]. This demonstrates that
there is sufficient qualitative information in early struc-
tural imaging to help guide clinicians in identifying pro-
gressive vs. responsive disease, with the exception of
pseudoprogression, a topic which is now finding its way
into the realm of imaging response criteria.
Historically, quantitative imaging criteria was first
addressed in 1979 by the WHO in their published
guidelines [2]. Since then, RECIST v1.0 [13] was pub-
lished in 2000 with subsequent revised criteria (version
1.1) in 2009 [14]. Each was developed in an attempt to
standardize reporting and facilitate comparison of ima-
ging response assessment within the context of clinical
oncology trials [4,11], however the results of this study
show that the ability to assess progressive disease via
quantitative radiological data remains limited. We found
that each of the MacDonald, RECIST and additional
thresholds, both uni and multi-dimensional, while speci-
f i cf o rp r o g r e s s i v ed i s e a s ew e r eh i g h l yi n s e n s i t i v e .T h i s
translated into a poor correlation with both PFS at one
year and OS at two years (Figure 4), therefore limiting
their usefulness as endpoint surrogates in clinical trials.
One obvious contributor to this effect is the issue of
pseudoprogression, in that pseudoprogressors will
always negatively impact the accuracy of progressive
thresholds based on standard structural imaging. Recent
updates in response assessment criteria by the RANO
group (Response Assessment in Neuro-Oncology) have
included an effort to address these challenges by devel-
oping guidelines specific to the management of brain
tumors including parameters for disease progression
[15]. They suggest deferring the determination of pro-
gressive disease until ≥ 12 weeks after the completion of
RT, except in the case of a new lesion outside of the
radiation field and/or pathology proven progressive dis-
ease within the original tumor site. This recommenda-
tion aims to defer a change in clinical management until
pseuodprogression can be more reliably ruled out. How-
ever, as was mentioned previously the OS between pseu-
doprogressors identified at one month after RT is not
significantly different from non-progressors, and there-
fore if these patients could be identified more readily,
the truly progressive patients would avoid an additional
8 weeks of ineffective chemotherapy.
In contrast, metrics for defining responsive disease
performed much better in terms of both PFS and OS
(Figure 4), likely in part because identifying responders
is not marred by the issue of pseudoprogression and
also because intuitively, those with large reductions in
tumor burden will do better than those without. Clinical
trials showing evidence of radiological response in GBM
are therefore likely to have an increased clinical rele-
vance in terms of survival endpoints, than those focus-
ing on progressive characteristics. This is contrary to
the findings of Galanis et al who found that progressive
disease to be more predictive of OS. This difference is
probably multi-factorial, for one a variety of gliomas
were included as compared to solely GBM as in this
study. Secondly, the there was a smaller portion of
responders in the Galanis study, likely owing in part to
the addition of temozolomide to the treatment regiment
in this study. Finally, the timing of the imaging was later
in the Galanis study, 4 months post-induction of therapy
as compared to one month post-RT in our study. This
difference in timing may decrease the incidence of pseu-
doprogressors as a fraction may have already declared
themselves as true early progressors by that point,
thereby alleviating their negative statistical impact on
the progressive imaging thresholds. If true, it is concei-
vable that optimizing the timing of post-therapy follow-
up imaging could aid in of identification of pseudopro-
gressors. Our study only looked at a single imaging time
point, however further investigation into multiple ima-
ging time points would certainly be insightful. It is unli-
kely however that the answer to this challenging issue
lies in timing along, and as such an array of research
continues to look for potentially more robust and quan-
tifiable solutions. Many groups have looked at the use of
functional imaging modalities to augment standard ana-
tomical information. The addition of perfusion and dif-
fusion-weighted techniques are thought to be able to
provide information about tumor activity as a potential
biomarker of tumor progression [25]. As such, the role
of functional MRI (diffusion-weighted and perfusion) is
the subject of intense clinical investigation [26-33], and
recent findings have shown that diffusion-weighted ima-
ging can predict for OS and time-to-progression in high
grade glioma [29,30]. Furthermore, recent results by
Tsien et. al. have shown promise in using dynamic sus-
ceptibility contrast magnetic resonace imaging (DSC-
MRI) and parametric response maps measuring relative
cerebral blood volume to identify pseudoprogression
from true progression during therapy [34]. The role of
FLT-PET and molecular imaging is also being actively
investigated as a potential modality for imaging tumor
progression [35,36].
A primary limitation of our study lies in a relatively
small sample size of prospectively recruited Glioblastoma
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cohort for meaningful interpretation and future clinical
translation. Furthermore, as was mentioned above, our
study only investigated a single imaging time point (one
month post-RT), additional imaging would be useful
determining if there is an optimal time point, and what
that might be. Our study cohort had a significantly higher
median survival (26.2 mo. 95% CI 13.7 - not reached)
than expected from the literature (14.6 mo. 95% CI 13.2 -
16.8 [37]). Finally, baseline imaging in the study was per-
formed post-operatively, where resolving post-surgical
changes may have been a potential confounding factor in
the assessment of response. Strengths of this cohort
include a typical and balanced population demographic
in age, gender and size. Extent of surgery was also
balanced with ~50% undergoing gross total resection and
the remainder having either partial total resection or
biopsy alone. The extended length of follow-up (median
22 months) was also beneficial to this study.
Conclusion
We sought to evaluate early radiologic response criteria
relevant to clinical outcomes in patients with GBM treated
with concurrent chemotherapy and radiotherapy, and
found that a qualitative clinical impression of radiologic
progression at one month after therapy was predictive of
poor outcomes despite the confounding factor of treatment
effect (pseudoprogression). Quantitatively, we found that
response metrics were more indicative of outcome than
progressive indices and that there was a trend of volu-
metric data outperforming diameter or area thresholds,
however significance was not reached in this case. Further
investigation will focus on adding additional imaging time
points as well as adjunct functional imaging to better
understand progression features that may have a stronger
predictive value than structural geometric indices alone.
Additional material
Additional file 1: Table 1: Sensitivity and specificity metrics in
predicting 2 year overall survival according to various volume
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Additional file 2: Table 2: Sensitivity and specificity metrics in
predicting 2 year overall survival according to various area
thresholds, from baseline to one month after RT.
Additional file 3: Table 3: Sensitivity and specificity metrics in
predicting 2 year overall survival according to various diameter
thresholds, from baseline to one month after RT.
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